Boualem Sendid1,2, Nicolas Salvetat3, Helène Sarter4,5, Severine Loridant1,2, Catherine Cunisse5, Nadine François1,2, Rachid Aijjou1,2, Patrick Gelé6, Jordan Leroy1,2, Dominique Deplanque6,7, Samir Jawhara1, Dinah Weissmann3, Pierre Desreumaux4,8, Corinne Gower-Rousseau4,5, Jean Frédéric Colombel8,9, Daniel Poulain1,2. 1. INSERM U1285, CNRS UMR 8576, Glycobiology in Fungal Pathogenesis and Clinical Applications, Université de Lille, F-59000 Lille, France. 2. Pôle de Biologie-Pathologie-Génétique, Institut de Microbiologie, Service de Parasitologie Mycologie, CHU Lille, F-59000 Lille, France. 3. ALCEDIAG Sys2Diag/CNRS UMR 9005 Parc Euromédecine Cap Delta, 1682 Rue de la Valsière, CEDEX 4, 34184 Montpellier, France. 4. U1286-INFINITE-Institute for Translational Research in Inflammation, INSERM, Université de Lille, F-59000 Lille, France. 5. CHU Lille, Unité de Biostatistiques, Pôle de Santé Publique, F-59000 Lille, France. 6. Biological Resources Centre, Lille University Hospital, F-59000 Lille, France. 7. INSERM, CHU Lille, CIC 1403-Centre d'Investigation Clinique, Université de Lille, F-59000 Lille, France. 8. CHU Lille, Service d'Hépato-Gastroentérologie, F-59000 Lille, France. 9. Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Abstract
BACKGROUND AND AIMS: This study prompted by growing evidence of the relationship between the yeast Candida albicans and Crohn's disease (CD) was intended to assess the effect of a 6-month course of the antifungal fluconazole (FCZ) on post-operative recurrence of CD. METHODS: Mycological samples (mouth swabs and stools) and serum samples were collected from 28 CD patients randomized to receive either FCZ (n = 14) or placebo (n = 14) before surgical resection. Serological analysis focused on levels of calprotectin, anti-glycan antibodies, and antibody markers of C. albicans pathogenic transition. Levels of galectin-3 and mannose binding lectin (MBL) involved in C. albicans sensing and inflammation were also measured. RESULTS: 1, 2, 3, and 6 months after surgery, endoscopy revealed recurrence in 5/12 (41.7%) patients in the FCZ group and 5/9 (55.6%) in the placebo group, the small cohort preventing any clinical conclusions. In both groups, surgery was followed by a marked decrease in C. albicans colonization and biomarkers of C. albicans pathogenic transition decreased to non-significant levels. Anti-glycan antibodies also decreased but remained significant for CD. Galectin-3 and calprotectin also decreased. Conversely, MBL levels, which inversely correlated with anti-C. albicans antibodies before surgery, remained stable. Building biostatistical multivariate models to analyze he changes in antibody and lectin levels revealed a significant relationship between C. albicans and CD. CONCLUSION: Several combinations of biomarkers of adaptive and innate immunity targeting C. albicans were predictive of CD recurrence after surgery, with area under the curves (AUCs) as high as 0.86. FCZ had a positive effect on biomarkers evolution. ClinicalTrials.gov ID: NCT02997059, 19 December 2016. University Hospital Lille, Ministry of Health, France. Effect of Fluconazole on the Levels of Anti-Saccharomyces cerevisiae Antibodies (ASCA) After Surgical Resection for Crohn's Disease. Multicenter, Randomized, and Controlled in Two Parallel Groups Versus Placebo.
RCT Entities:
BACKGROUND AND AIMS: This study prompted by growing evidence of the relationship between the yeastCandida albicans and Crohn's disease (CD) was intended to assess the effect of a 6-month course of the antifungal fluconazole (FCZ) on post-operative recurrence of CD. METHODS: Mycological samples (mouth swabs and stools) and serum samples were collected from 28 CD patients randomized to receive either FCZ (n = 14) or placebo (n = 14) before surgical resection. Serological analysis focused on levels of calprotectin, anti-glycan antibodies, and antibody markers of C. albicans pathogenic transition. Levels of galectin-3 and mannose binding lectin (MBL) involved in C. albicans sensing and inflammation were also measured. RESULTS: 1, 2, 3, and 6 months after surgery, endoscopy revealed recurrence in 5/12 (41.7%) patients in the FCZ group and 5/9 (55.6%) in the placebo group, the small cohort preventing any clinical conclusions. In both groups, surgery was followed by a marked decrease in C. albicans colonization and biomarkers of C. albicans pathogenic transition decreased to non-significant levels. Anti-glycan antibodies also decreased but remained significant for CD. Galectin-3 and calprotectin also decreased. Conversely, MBL levels, which inversely correlated with anti-C. albicans antibodies before surgery, remained stable. Building biostatistical multivariate models to analyze he changes in antibody and lectin levels revealed a significant relationship between C. albicans and CD. CONCLUSION: Several combinations of biomarkers of adaptive and innate immunity targeting C. albicans were predictive of CD recurrence after surgery, with area under the curves (AUCs) as high as 0.86. FCZ had a positive effect on biomarkers evolution. ClinicalTrials.gov ID: NCT02997059, 19 December 2016. University Hospital Lille, Ministry of Health, France. Effect of Fluconazole on the Levels of Anti-Saccharomyces cerevisiae Antibodies (ASCA) After Surgical Resection for Crohn's Disease. Multicenter, Randomized, and Controlled in Two Parallel Groups Versus Placebo.
Authors: Joana Torres; Francesca Petralia; Takahiro Sato; Pei Wang; Shannon E Telesco; Rok Seon Choung; Richard Strauss; Xiao-Jun Li; Renee M Laird; Ramiro L Gutierrez; Chad K Porter; Scott Plevy; Fred Princen; Joseph A Murray; Mark S Riddle; Jean-Frederic Colombel Journal: Gastroenterology Date: 2020-03-09 Impact factor: 22.682
Authors: Rodrigo Papa Gobbi; Nicolás De Francesco; Constanza Bondar; Cecilia Muglia; Fernando Chirdo; Martín Rumbo; Andrés Rocca; Marta A Toscano; Alicia Sambuelli; Gabriel A Rabinovich; Guillermo H Docena Journal: Biofactors Date: 2016-02-01 Impact factor: 6.113
Authors: Agnes Fermin Lee; Huan-Yuan Chen; Lei Wan; Sheng-Yang Wu; Jhang-Sian Yu; Annie C Huang; Shi-Chuen Miaw; Daniel K Hsu; Betty A Wu-Hsieh; Fu-Tong Liu Journal: Am J Pathol Date: 2013-08-03 Impact factor: 4.307
Authors: B Sendid; N Dotan; S Nseir; C Savaux; P Vandewalle; A Standaert; F Zerimech; B P Guery; A Dukler; J F Colombel; D Poulain Journal: Clin Vaccine Immunol Date: 2008-10-29
Authors: L Choteau; M Parny; N François; B Bertin; M Fumery; L Dubuquoy; K Takahashi; J-F Colombel; T Jouault; D Poulain; B Sendid; S Jawhara Journal: Mucosal Immunol Date: 2015-10-07 Impact factor: 7.313